August 22, 2024 03:44 PM EDT

FDA to host adcomm on PD-L1 as a predictive biomarker for checkpoint inhibitors

Nicole DeFeudis

Editor

The FDA is assembling its Oncologic Drugs Advisory Committee next month to discuss whether a biomarker should be used to select patients with certain stomach …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA to host adcomm on PD-L1 as a predictive biomarker for checkpoint inhibitors

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Breaking down silos with a new quantitative approach to drug development

FDA to host ad­comm on PD-L1 as a pre­dic­tive bio­mark­er for check­point in­hibitors

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA to host adcomm on PD-L1 as a predictive biomarker for checkpoint inhibitors